<DOC>
	<DOCNO>NCT02734251</DOCNO>
	<brief_summary>The present randomize , double-blind , placebo-controlled crossover trial aim evaluate effect Relora supplementation response induce stress produce combination cognitive physiologic stressor healthy men woman . The effect supplement , compare placebo , evaluate use measure assess anxiety [ State-Trait Anxiety Inventory-Part 1 ( STAI-Part 1 ) , mood [ Bond-Lader Visual Analog Scale ( VAS ) ] , hypothalamic-pituitary-adrenal axis activation ( salivary cortisol ) cognitive function ( cognitive flexibility , reaction time , process speed , attention , sustained attention , work memory , executive function ) . Testing complete begin end 7-d supplementation period active placebo product assess acute effect `` acute-on-chronic '' effect follow one week daily use .</brief_summary>
	<brief_title>Effect Relora Supplement Anxiety , Cognitive Performance &amp; Mood Tested After Induced Stress</brief_title>
	<detailed_description />
	<criteria>1 . Subject male female , 2159 year age , inclusive . 2 . Subject judge Investigator general good health basis medical history screen laboratory test . 3 . Subject BMI 18.5029.99 kg/m2 , inclusive , visit 1 ( day 6 ) . 4 . Subject nonuser nicotine product 6 month prior visit 1 ( day 6 ) . 5 . Subject willing maintain habitual diet physical activity pattern throughout study period . 6 . Subject willing able attend screen visit 4 test visit last ~4 h ( visit 2 5 ; day 1 7 Period I Period II , respectively ) . 7 . Subject able maintain immersion nondominant hand , include forearm , ice water ( 04°C ) ≥30 second CPT visit 1 ( day 6 ) . 8 . Subject willing refrain alcohol 12 h prior test visit ( visit 2 5 ; day 1 7 Periods I II , respectively ) limit alcohol consumption one serving alcohol ( 1 drink = 12 oz beer , 5 oz wine , 1.5 oz hard liquor ) 24 h prior test visit ( visit 2 , 3 , 4 , 5 ; day 1 7 Period I Period II , respectively ) . 9 . Subject willing limit caffeinecontaining beverages/foods/products consume breakfast meal test visit day ( visit 2 , 3 , 4 , 5 ; day 1 7 Period I Period II , respectively ) 1 serve ( 150 mg ) ≥2 h prior test visit . 10 . Subject willing consume hearty breakfast daily basis throughout study period replication time quantity food beverage consume visit 2 ( day 1 ) breakfast meal morning subsequent test visit ( visit 3 5 ; day 7 Period I day 1 7 Period II ) . 11 . Subject willing replicate timing dose necessary morning medication and/or supplement take prior come clinic visit 2 ( day 1 ) subsequent test visit ( visit 3 5 ; day 7 Period I day 1 7 Period II ) . 12 . Subject willing able comfortably abstain caffeine throughout duration test visit ( ~5 h ; visit 2 , 3 , 4 , 5 ; day 1 7 Period I Period II , respectively ) . 13 . Subject understands study procedure sign form document informed consent participate study authorization release relevant protect health information study Investigator willing complete study procedure . 1 . Subject history presence clinically important cardiac , renal , hepatic , endocrine ( include Type 1 Type 2 diabetes mellitus ) , pulmonary , biliary , pancreatic , neurologic disorder . 2 . Subject history diagnose generalized anxiety , and/or major psychiatric disorder ( ) , diagnose depression . 3 . Subject history diagnose depression 2 year prior visit 1 ( day 6 ) and/or score 17 high Beck Depression Scale . 4 . Subject abnormal comprehensive metabolic panel and/or complete blood count test result clinical significance . A reflex HbA1C may assess subject blood glucose ≥126 mg/dL determine glycemic status , discretion Investigator . 5 . Subject test positive substance include urine drug screen ( i.e. , cocaine , tetrahyrdocannabinol , opiates , amphetamine , methamphetamine , phencyclidine , benzodiazepine , barbiturate , methadone , oxycodone , methylenedioxymethamphetamine , propoxyphene ) . 6 . Subject unable understand and/or perform require test base practice test result . 7 . Subject history unconventional sleep pattern ( e.g. , night shift ) , diagnose sleep disorder , chronic medical condition may impact mood and/or cognition level , judgment Investigator . 8 . Subject uncontrolled hypertension ( systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥100 mm Hg ) visit 1 ( day 6 ) . 9 . Subject active infection signs/symptoms infection . Test visit reschedule allow subject symptomfree type systemic infection least 5 d. 10 . Subject know allergy sensitivity ingredient study product . 11 . Subject use recreational drug prescription medication potential influence mood , anxiety , cognitive function , and/or modulate autonomic nervous system ( include narcotic ( opioid ) pain medication ) within 4 week visit 1 ( day 6 ) . 12 . Subject use nicotine withdrawal/replacement therapy within 6 month visit 1 ( day 6 ) . 13 . Subject use overthecounter medication , supplement , and/or product , may influence mood , anxiety , and/or cognitive function within 2 week visit 1 ( day 6 ) . 14 . Subject history cancer within 5 year prior visit 1 ( day 6 ) , except nonmelanoma skin cancer . 15 . Subject female , pregnant , plan pregnant study period , lactating , childbearing potential unwilling commit use medically approve form contraception throughout study period . The method contraception must record source documentation . 16 . Subject current recent history ( past 12 month visit 1 , day 6 ) strong potential drug alcohol abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1.5 oz hard liquor ) . 17 . Subject expose nonregistered drug product within 30 prior visit 1 ( day 6 ) . 18 . Individual condition Investigator believe would interfere his/her ability provide inform consent , comply study protocol , might confound interpretation study result , put subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy mood</keyword>
	<keyword>Stress management</keyword>
	<keyword>Relora</keyword>
	<keyword>Healthy subject</keyword>
</DOC>